COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic (CoVAPid2)

May 20, 2026 updated by: University Hospital, Lille

Incidence of Ventilator-associated Lower Respiratory Tract Infections Among Patients With SARS-CoV-2 Infection Throughout the First and the Second Wave of the Pandemic: a European Comparative Cohort Study

Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.

Study Overview

Status

Withdrawn

Conditions

Severe COVID-19

Detailed Description

CoVAPid2 is a multicenter retrospective observational cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic. Patients with confirmed SARS-CoV-2 community-acquired pneumonia and receiving invasive mechanical ventilation for more than 48h in the participating ICUs from the start of COVID pandemic are eligible for this study. Consecutive patients will be included from the beginning of the first wave (starting on 01-01-2020, data already collected in the CoVAPid1 study) and the second wave (starting on 10-01-2020). 10-20 patients per wave will be included in each center. VAT and VAP are defined using clinical, radiological and quantitative microbiological criteria.

Study Type

Observational

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Lille, France, 59037
    - Hop Salengro - Hopital B Chr Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Sampling Method

Probability Sample

Study Population

Patients with confirmed SARS-CoV-2 community-acquired pneumonia and receiving invasive mechanical ventilation for more than 48h in the participating ICUs from the start of COVID pandemic are eligible for this study.

Description

Inclusion Criteria:

Major (18 years and older)
Admitted to the ICU
Intubated and mechanically ventilated for more than 48 hours
With a confirmed community-acquired SARS-CoV2 pneumonia

Exclusion Criteria:

Refusal to participate
Lack of social security coverage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
SARS-CoV-2 first wave Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the first wave of the pandemic, starting on 01-01-2020
SARS-CoV-2 second wave Patients with confirmed SARS-CoV-2 infection and receiving invasive mechanical ventilation for more than 48h, in the second wave of the pandemic, starting on 10-01-2020

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Cumulative incidence of ventilator-associated lower respiratory tract infection (ventilator-associated pneumonia and ventilator associated tracheobronchitis) Time Frame: from day 3 of mechanical ventilation to extubation or day 28 post-intubation	from day 3 of mechanical ventilation to extubation or day 28 post-intubation

Secondary Outcome Measures

Outcome Measure	Time Frame
Cumulative incidence of ventilator-associated tracheobronchitis Time Frame: from day 3 of mechanical ventilation to extubation or day 28 post-intubation	from day 3 of mechanical ventilation to extubation or day 28 post-intubation
Cumulative incidence of ventilator-associated pneumonia Time Frame: from day 3 of mechanical ventilation to extubation or day 28 post-intubation	from day 3 of mechanical ventilation to extubation or day 28 post-intubation
Prevalence of early bacterial coinfection Time Frame: from day 0 to day 2 of mechanical ventilation	from day 0 to day 2 of mechanical ventilation
Cumulative incidence of COVID-associated pulmonary aspergillosis Time Frame: from day 3 of mechanical ventilation to extubation or day 28 post-intubation	from day 3 of mechanical ventilation to extubation or day 28 post-intubation
ICU mortality Time Frame: at day 28	at day 28
Mortality Time Frame: at day 28	at day 28
Duration of mechanical ventilation (number of days under mechanical ventilation) Time Frame: from the start of mechanical ventilation to extubation or day 28 after intubation	from the start of mechanical ventilation to extubation or day 28 after intubation
Duration of ICU stay (number of days in the ICU) Time Frame: from the ICU admission to discharge or day 28 after admission	from the ICU admission to discharge or day 28 after admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Investigators

Principal Investigator: Saad NSEIR, MD,PhD, University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2021

Primary Completion (Actual)

December 1, 2023

Study Completion (Actual)

December 1, 2023

Study Registration Dates

First Submitted

February 24, 2022

First Submitted That Met QC Criteria